Therapy Areas: Infectious Diseases
Bioharmony Therapeutics, Boehringer Ingelheim Team to Advance Bacteriophage Lysin Therapeutics for the Treatment of Multi-Drug Resistant Bacterial Infections
16 January 2019 - - US-based biopharmaceutical company Bioharmony Therapeutics, Inc has entered into a Collaborative Research and Licensing Agreement with German pharmaceutical company Boehringer...
Phico Therapeutics Names Financial Director, Two Non-Executive Directors
16 January 2019 - - UK-based biotechnology company Phico Therapeutics Ltd has appointed Andrew Armour as financial director, and professor Mark Wilcox and David Beadle as non-executive directors, the ...
Berman to Head R and D at Immunocore
16 January 2019 - - UK-based T Cell Receptor biotechnology company Immunocore Ltd has named David Berman as its new head of research and development, the company said.

David joined Immuno...
TB Alliance welcomes Jan Lundberg to board
16 January 2019 - Tuberculosis drug company TB Alliance revealed on Tuesday the addition of Jan Lundberg to its board of directors.Dr Lundberg spent eight years as president of Lilly Research Laborato...
Alnylam Pharmaceuticals Prices USD 387.5m Common Stock Offering
15 January 2019 - - US-based RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) has priced of an underwritten public offering of 5m shares of its common stock at a public offering ...
FDA Approves Expanded Use of Adacel Vaccine for Repeat Vaccination
15 January 2019 - - The US Food and Drug Administration has approved the expanded use of Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed) to include rep...
Related Headlines

Sanofi wins US FDA approval for expanded repeat vaccination of Adacel against tetanus, diphtheria and pertussis

hVIVO's phase II vaccine flu study reveals positive result

Quanterix Extends Oncology Footprint with Accelerated Launch of Next Gen SP-X Platform and CorPlex Validated 10-Plex

NantKwest Launches Merkel Cell Carcinoma Phase II Trial Deploying Novel Triple Combination of off-the-Shelf Natural Killer haNK Cell Therapy with Superagonist IL-15 Cytokine Therapy and PD-L1 Checkpoint Inhibitor Therapy

Mobidiag Receives CE-IVD Marking for Novodiag CarbaR+ Test, Allowing Rapid Molecular Testing for 'Superbacteria' and Associated Drug Resistance

Veristat Touts Support for 12% of all FDA NME Approvals in 2018, a Record-Setting Year for FDA Approvals

Immunocore Names Jallal as CEO

Immunocore names Bahija Jallal new chief executive and director

Sanofi invests in BioNTech

Hookipa Achieves First Research Milestone in HIV Collaboration and License Agreement with Gilead

US FDA Clears Precigen IND to Initiate Phase 1/1b Study for First-in-Class PRGN-3006 UltraCAR-T Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome

ILiAD Biotechnologies Secures Up to USD 20m of Financing and Phase 2a BPZE1 Pertussis Vaccine Trial Initiates at Vanderbilt University Medical Center

Dicerna Closes Global Licensing and Research Collaboration with Eli Lilly and Company

Hookipa Doses First Patient in a Phase 2 Clinical Trial of Prophylactic Vaccine Candidate HB-101 against Cytomegalovirus

Teneobio, Selexis Enter Second Services Agreement to Develop Research Cell Banks